220 related articles for article (PubMed ID: 11406571)
1. A novel N-ras mutation in malignant melanoma is associated with excellent prognosis.
Demunter A; Ahmadian MR; Libbrecht L; Stas M; Baens M; Scheffzek K; Degreef H; De Wolf-Peeters C; van Den Oord JJ
Cancer Res; 2001 Jun; 61(12):4916-22. PubMed ID: 11406571
[TBL] [Abstract][Full Text] [Related]
2. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression.
Omholt K; Karsberg S; Platz A; Kanter L; Ringborg U; Hansson J
Clin Cancer Res; 2002 Nov; 8(11):3468-74. PubMed ID: 12429636
[TBL] [Abstract][Full Text] [Related]
3. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9.
Kumar R; Angelini S; Hemminki K
Oncogene; 2003 Dec; 22(58):9217-24. PubMed ID: 14681681
[TBL] [Abstract][Full Text] [Related]
4. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma.
Demunter A; Stas M; Degreef H; De Wolf-Peeters C; van den Oord JJ
J Invest Dermatol; 2001 Dec; 117(6):1483-9. PubMed ID: 11886512
[TBL] [Abstract][Full Text] [Related]
5. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype.
Albino AP; Nanus DM; Mentle IR; Cordon-Cardo C; McNutt NS; Bressler J; Andreeff M
Oncogene; 1989 Nov; 4(11):1363-74. PubMed ID: 2682463
[TBL] [Abstract][Full Text] [Related]
6. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma.
van Elsas A; Zerp SF; van der Flier S; Krüse KM; Aarnoudse C; Hayward NK; Ruiter DJ; Schrier PI
Am J Pathol; 1996 Sep; 149(3):883-93. PubMed ID: 8780392
[TBL] [Abstract][Full Text] [Related]
7. K-ras codon 12 and 13 mutations are correlated with differential patterns of tumor cell dissemination in colorectal cancer patients.
Conzelmann M; Linnemann U; Berger MR
Int J Oncol; 2004 Jun; 24(6):1537-44. PubMed ID: 15138598
[TBL] [Abstract][Full Text] [Related]
8. Analysis of mutations of neurofibromatosis type 1 gene and N-ras gene in acute myelogenous leukemia.
Lee YY; Kim WS; Bang YJ; Jung CW; Park S; Yoon WJ; Cho KS; Kim IS; Jung TJ; Choi IY
Stem Cells; 1995 Sep; 13(5):556-63. PubMed ID: 8528106
[TBL] [Abstract][Full Text] [Related]
9. Associations between dietary intake and Ki-ras mutations in colon tumors: a population-based study.
Slattery ML; Curtin K; Anderson K; Ma KN; Edwards S; Leppert M; Potter J; Schaffer D; Samowitz WS
Cancer Res; 2000 Dec; 60(24):6935-41. PubMed ID: 11156393
[TBL] [Abstract][Full Text] [Related]
10. Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations.
Demunter A; Libbrecht L; Degreef H; De Wolf-Peeters C; van den Oord JJ
Mod Pathol; 2002 Apr; 15(4):454-61. PubMed ID: 11950921
[TBL] [Abstract][Full Text] [Related]
11. Incidence of p53 and ras gene mutations in DMBA-induced rat leukemias.
Wei S; Kito K; Miyoshi A; Matsumoto S; Kauzi A; Aramoto T; Abe Y; Ueda N
J Exp Clin Cancer Res; 2002 Sep; 21(3):389-96. PubMed ID: 12385583
[TBL] [Abstract][Full Text] [Related]
12. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
13. Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma.
Alsina J; Gorsk DH; Germino FJ; Shih W; Lu SE; Zhang ZG; Yang JM; Hait WN; Goydos JS
Clin Cancer Res; 2003 Dec; 9(17):6419-25. PubMed ID: 14695143
[TBL] [Abstract][Full Text] [Related]
14. Frequency of RAS gene mutation and its cooperative genetic events in Southeast Asian adult acute myeloid leukemia.
Auewarakul CU; Lauhakirti D; Tocharoentanaphol C
Eur J Haematol; 2006 Jul; 77(1):51-6. PubMed ID: 16573741
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of specific KRAS mutations in lung adenocarcinomas.
Siegfried JM; Gillespie AT; Mera R; Casey TJ; Keohavong P; Testa JR; Hunt JD
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):841-7. PubMed ID: 9332768
[TBL] [Abstract][Full Text] [Related]
16. Detection of B-RAF and N-RAS mutations in human melanoma.
Goydos JS; Mann B; Kim HJ; Gabriel EM; Alsina J; Germino FJ; Shih W; Gorski DH
J Am Coll Surg; 2005 Mar; 200(3):362-70. PubMed ID: 15737846
[TBL] [Abstract][Full Text] [Related]
17. ras mutations in human melanotic lesions: K-ras activation is a frequent and early event in melanoma development.
Shukla VK; Hughes DC; Hughes LE; McCormick F; Padua RA
Oncogene Res; 1989; 5(2):121-7. PubMed ID: 2691957
[TBL] [Abstract][Full Text] [Related]
18. Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?
Camps C; Sirera R; Bremnes R; Blasco A; Sancho E; Bayo P; Safont MJ; Sánchez JJ; Tarón M; Rosell R
Lung Cancer; 2005 Dec; 50(3):339-46. PubMed ID: 16139926
[TBL] [Abstract][Full Text] [Related]
19. BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
Kumar R; Angelini S; Czene K; Sauroja I; Hahka-Kemppinen M; Pyrhönen S; Hemminki K
Clin Cancer Res; 2003 Aug; 9(9):3362-8. PubMed ID: 12960123
[TBL] [Abstract][Full Text] [Related]
20. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma.
Jassem J; Jassem E; Jakóbkiewicz-Banecka J; Rzyman W; Badzio A; Dziadziuszko R; Kobierska-Gulida G; Szymanowska A; Skrzypski M; Zylicz M
Cancer; 2004 May; 100(9):1951-60. PubMed ID: 15112277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
